Conference Schedule - Updated May 26, 2015 
Monday June 8, 2015
8:00 am
 Mary Jeanne Kreek, MD
Senior Attending Physician
Patrick E. and Beatrice M. Haggerty Professor
Laboratory of the Biology of Addictive Diseases
The Rockefeller University, New York, New York
    Mary Jeanne Kreek, MD, is a graduate of Wellesley College and also of the Columbia University College of Physicians & Surgeons, where she received the MD degree.  Dr. Kreek joined The Rockefeller Institute in 1964, and, with the late Dr. Vincent P. Dole and the late Dr. Marie Nyswander, who also joined the team at that time, performed the initial studies of the use of a long-acting opioid agonist, methadone, in chronic management of heroin addiction. Dr. Kreek is Patrick E. and Beatrice M. Haggerty Professor and Head of the Laboratory of the Biology of Addictive Diseases at The Rockefeller University, and Senior Physician of The Rockefeller University Hospital.  Until March 2008, Dr. Kreek had held a Senior Scientist Award from NIH-NIDA for many years (K05-00049).  She was Principal Investigator and Research Director of an NIH-NIDA P60 Center grant (DA-05130) – “Treatment of Addictions: Biological Correlates” until April 2013.  She also has grants from NIH-NIDA.  She is author or co-author of over 350 peer reviewed research papers and over 150 invited concept reviews and reports.

    By molecular, cell biological, neurochemical, behavioral, basic clinical research, and human molecular genetics studies, she documented the role of the endogenous opioid system in cocaine, alcohol and heroin addiction: 
(1) mu opioid receptor-endorphin peptides in the “rewarding” effects and (2) kappa opioid receptor-dynorphins in countermodulatory effects including suppression of dopamine.   Her group also identified multiple novel polymorphisms in the coding and non-coding regions of human mu and kappa opioid receptor genes and shown associations of these two opioid receptor genes, as well as two opioid peptide genes, dynorphin and enkephalin, with three different specific addictive diseases, opiate addiction, cocaine addiction and alcoholism.  Her lab also discovered over 20 addictive gene variants associated with opioid addiction leading to papers on neurotransmitters and stress responsive genes.  Her laboratory is currently studying the functional specific gene variants and selected epigenetics questions in humans and in rodent models.  In the lab she also studies, in cells, animals and humans, the effects of several kappa gene regulatory agents including agonists, partial agonists, and antagonists and is working on new pharmacological agents. 

    In collaboration with the CDC in 1983-84, she was the first to identify parenteral drug users as the second risk group for acquiring HIV-1/AIDS infection.  She has conducted many studies on hepatitis B, hepatitis delta and hepatitis C, alone, and in combination with AIDS in the addictive disease populations.  

    She has received several awards for her scientific research, including the Betty Ford Award from AMERSA (1996), the R. Brinkley Smithers Distinguished Scientist Award and Lecture of ASAM (1999), the Nathan B. Eddy Memorial Award for Lifetime Excellence in Drug Abuse Research (1999) and the Marian Fischman Award (2005), both presented by the College on Problems of Drug Dependence. In 2000, she was conferred with the Doctor Honoris Causa by the University of Uppsala, Sweden, and was made a Fellow of the New York Academy of Sciences. 

    In 2004, Dr. Kreek was awarded the Columbia University College of Physicians & Surgeons Alumni Association’s Gold Medal for Lifetime Distinguished Achievements in Academic Medicine. In 2005, she received the International Narcotics Research Conference Founder’s Award.  An Honorary Fellowship in the American College of Psychiatrists was conferred on Dr. Kreek in 2006.  In 2007, Dr. Kreek was awarded a Doctor Philosophiae Honoris Causa from Tel Aviv University, Israel.  In 2010, Dr. Kreek was awarded a Laurea Doctor Honoris Causa by the University of Bologna, Italy.  In 2012, Dr. Kreek was awarded the Wellesley College Alumnae Achievement Award and in 2014, she was awarded the Lifetime Science Award by the National Institute on Drug Abuse.
Monday, June 8, 2015
11:30 am - 12:30 pm
The Honorable Charles D. Baker, Jr.
Governor of Massachusetts
Massachusetts State House
  Charlie Baker was inaugurated on January 8th, 2015 as the 72nd Governor of the Commonwealth of Massachusetts.

Elected in November of 2014 on a platform of making Massachusetts great for everyone, Governor Baker’s arrival in the Corner Office continues a long, successful career in both the private sector and public service where he has worked hard to put the people of Massachusetts first.

Governor Baker is committed to making Massachusetts a truly great place to live, work, start a business and raise a family. As Governor, he has pledged to work toward a growing economy with family-sustaining jobs; ensure that schools across the Commonwealth provide opportunity for every child regardless of zip code; and make Beacon Hill a true partner with our local governments to create safer and thriving communities across Massachusetts. Over the course of his career, Governor Baker has been a highly successful leader of complex organizations in business and in government. As a cabinet secretary under Governors William Weld and Paul Cellucci, Baker helped lead efforts to reform and modernize state government. During his time as Chief Executive Officer of Harvard Pilgrim Health Care, Baker turned a company on the brink of bankruptcy into the nation’s highest ranked health care provider for six straight years.

   As a member of the Weld and Cellucci Administrations in the 1990s, Baker helped turn a billion-dollar deficit into a surplus, create a half million jobs, and enact an ambitious education reform agenda. First asked to serve as Secretary of Health and Human Services in 1992, Baker led efforts to make Massachusetts’ social service system more humane, cost-effective and responsive to the needs of the Commonwealth’s residents. In 1994, Baker was appointed Secretary of Administration and Finance, overseeing a number of cost-saving reforms, modernizing state government and making it more efficient. Governor Baker was recognized for his leadership and innovation by the National Governors’ Association in 1998 who rewarded him with the Distinguished Service Award.

   As Chief Executive Officer of Harvard Pilgrim Health Care from 1999 to 2009, Baker led the company out of receivership to become the top healthcare plan in the country for member satisfaction and clinical effectiveness. During Baker’s tenure, Harvard Pilgrim was named one of Boston Business Journal’s “Best Places To Work” for seven years in a row.

   Raised in Needham, Baker attended Massachusetts public schools and is a graduate of Harvard College. He went on to earn a Master’s of Business Administration from the Kellogg Graduate School of Management at Northwestern University. 

2015 Conference Schedule
Sunday, June 7, 2015
Conference Hours 8:30 am - 5:30 pm, Registration open 7:00 am - 5:00 pm
8:30 am - 9:00 am
Conference Opening and Welcome 
Paul A. Sloan, MD, Mellar Davis, MD
 9:00 am - 10:30 pm
Intensive training on ER/LA Opioids
Great primer and/or refresher program
Paul A. Sloan, MD, Mellar Davis, MD
10:30 am - 11:00 am
Break with Exhibitors and Poster Presenters
   11:00 am - 12:30 pm
Intensive training on ER/LA Opioids
Great primer and/or refresher program
Paul A. Sloan, MD, Mellar Davis, MD
12:30 pm - 1:30 pm
Lunch Break with Exhibitors, Poster Presenters or Satellite Symposia
Lunch provided by ICOO2015 organizers - not industry sponsored
12:30 pm - 1:30 pm
Satellite Symposia


The US Center for Disease Control reports that drug overdose death rates have more
 than doubled between 1999 and 2013. In 2013, 71.3% of deaths from pharmaceutical overdose involved opioid analgesics. Methods to mitigate the risk of opioid overdose
 across multiple healthcare settings are needed. 

Opioid overdose can occur both in patients prescribed opioids for pain and persons
 using prescription opioids diverted from medical use; overdoses can occur due to misunderstanding, accident, or intentional overuse and are not limited to individuals
 addicted to opioids. In an effort to control opioid overdose, which results globally
 in an estimated 69,000 deaths per year, the World Health Organization recommends increasing access to naloxone.

This session will use case studies to review the identification of the at-risk patient and strategies to reduce prescription opioid overdose risk, focusing on the role of naloxone.
 It will review requisite counseling for potential users of naloxone and arguments
 for selective versus universal co-prescribing of naloxone with opioids. Diverse
 state-mandated regulations governing availability of naloxone and liability protection
 for prescribers and administrators will be explored. Attitudes, approaches,
 and barriers to co-prescribing naloxone will be addressed so that this approach
 can be better understood and appropriately utilized.

Bob Twillman1, Seddon Savage2

1 American Academy of Pain Management, Dartmouth Medical School & Silver Hill Hospital
Non-CME Symposia sponsored by Indivior PLC
1:30 pm - 2:15 pm
Intrathecal and epidural administration of opioids in therapy-resistant
cancer pain syndromes: indications and practical considerations?
In this presentation the experience from a university-based pain center will be provided (covering over 100 patients) with the intrathecal administration of opioids in cancer pain syndromes which were resistant to (high doses of) systemic opioids.
Guy Hans, MD, PhD, Paul A. Sloan, MD
2:15 pm - 3:00 pm 
Reducing Opioid Misuse Among Chronic Pain Patients In Primary Care
This presentation will include the results of a prospective controlled trial
designed to examine the benefits of careful monitoring
of chronic pain patients within primary care.
Robert Jamison, PhD
3:00 pm - 3:30 pm  
Pharmacogenomics of Opioids: Clinical Translation is Premature
For opioids requiring CYP2D6 to form active metabolites, poor metabolizers
should have no pain reduction but this has not been shown clinically.
Ultrarapid metabolizers have toxicity. The mu receptor gene 118A>G
causes higher dosage requirements. Clinical translation of opioid genetics
is premature as many pain and addiction phenotype factors contribute.
Andrew Somogyi, MD
3:30 pm - 4:00 pm
Break with Exhibitors and Poster Presenters 
4:00 pm - 4:45 pm   
Morphine-triggered relapse to cocaine-seeking behavior in laboratory rats
is attenuated by a highly-selective dopamine D3 receptor antagonist
Re-exposure to addictive drugs triggers relapse. Cross-triggering between drug classes is common (e.g., opioids triggering cocaine or amphetamine craving). Dopamine D3 receptor antagonists show extraordinary promise as anti-addiction medications in animal models. The D3 antagonist SB277011A significantly attenuates morphine-triggered relapse to cocaine-seeking behavior in the conditioned place preference animal model.
Eliot Gardner, PhD
4:45 pm - 5:30 pm   
Transforming Opioid Prescribing Practice at a Comprehensive Cancer Center
We sought to examine opioid prescribing practices by clinician survey at a comprehensive cancer center (CCC).  A task force was convened to examine the issue and a Medication Management Agreement (MMA) and patient education document were created. We hoped to transform prescribing practices within a population of oncology patients.
Lida Nabati, MD, Douglas Brandoff MD

 Monday, June 8, 2015
Conference Hours 8:00 am - 5:15 pm, Registration open 7:00 am - 5:00 pm
 8:00 am - 8:45 am
Keynote: Methadone maintenance:
An effective treatment for opioid addiction & for chronic pain
Mary Jeanne Kreek, MD
8:45 am - 9:15 am
Methadone: Update on Safety and Dosing Guidelines

The American Pain Society and other groups recently published safety guidelines
on methadone dosing and suggested monitoring parameters.  This presentation will provide an overview of these guidelines and will include case-based illustrative examples. Application in special populations such as end of life care will also be addressed.
Mary Lynn McPherson, PharmD, BCPS,CPE
9:15 am - 9:45 am
New Drugs and Drug News in Pain Management

Over 100 new drugs and dosage formulations are approved by the FDA every year, and many of them are used to relieve pain or analgesic-induced adverse effects. This presentation will provide cutting-edge, practical information on these products and their appropriate use.
Mary Lynn McPherson, PharmD, BCPS,CPE
9:45 am - 10:15 am
Oxycodone/Naloxone PR Combination Analgesic:
Where does it Belong in the Opioid Therapy?
This presentation will review the pharmacology and evidence for Targiniq ER in non-cancer chronic pain, cancer pain, neuropathic pain and postoperative pain.
A critique will be made of studies and then the potential place of this analgesic
in opioid therapy will be outlined based on the data.
Mellar Davis, MD
10:15 am - 10:45 am
Break with Exhibitors and Poster Presenters
10:45 am - 11:30 am
Dodging Elusive and Miscalculated Opioid Risks:
A Primer on Pharmacogenetics and Unsuspected Drug Interactions
(with prescribed and illicit synthetics)
Fatal drug interactions between opioids and sedative-hypnotics have been well publicized and studied. Less publicized are serious drug interactions between pain medications and illicit synthetic designer drugs. Pharmacologic interactions between prescription opioids and synthetics have not been studied extensively.  Unsuspected pharmacogenetic and p-gylocoprotein interactions also is largely underappreciated by clinicians.
Jeffrey Fudin, BS, PharmD, DAAPM, FCCP, FASHP
11:30 am - 12:30 pm
 Keynote: Opioid Epidemic in Massachusetts
Governor Charlie Baker will speak about the opioid abuse epidemic in Massachusetts
and the goals of the Opioid Addiction Working Group.

Massachusetts Governor Charlie Baker
12:30 pm - 1:30 pm
Lunch Break with Exhibitors, Poster Presenters or Satellite Symposia
Lunch provided by ICOO2015 organizers - not industry sponsored
12:30 pm - 1:30 pm
Satellite Symposia
Development and Validation of a Risk Index
 for Prescription Opioid Overdose
 and Serious Opioid-related Respiratory Depression

Eric Edwards, MD, PhD
Chief Medical Officer and VP Research & Development 
Non-CME Symposia sponsored by kaléo 
1:30 pm - 2:00 pm
Basic science of variability in opioid responses and analgesic tolerance:
Bridging basic science to clinical relevance

Gavril Pasternak, MD
2:00 pm - 2:30 pm
Chronic Pain Patients Who Fail Standard Opioid Dosages

There is a subgroup of severe chronic pain patients who fail to achieve pain relief
with standard opioid dosages of about 80 to 100 mg of morphine equivalence a day.
Our studies show that these patients have significant hormonal, genetic,
or metabolic abnormalities that help explain their treatment failure
Forest Tennant, MD, DrPH
2:30 pm - 3:15 pm 
Legal issues from a physician’s viewpoint
Carol Warfield, MD
Michael Barnes, Esq.
 3:15 pm - 3:45 pm
Break with Exhibitors and Poster Presenters 

3:45 pm - 4:30 pm
Perioperative Pain Management of Opioid Dependent Patients

Opioid dependent patients pose a considerable challenge to the perioperative physician. Pain management is a major concern in such patients. The speakers will address the magnitude of the problem, clinical and pathophysiological aspects, and management options while dealing with patients with opioid dependence.
Nalini Vadivelu, MBBS, MD, DNB
Lucy Chen, MD
Karina Gritsenko, MD
4:30 pm - 5:15 pm
Pain Management in Patients with Opioid Use Disorders
Pain management often presents a challenge in patients with alcohol or drug use disorders, especially opioid use disorders. Treatment of opioid dependence with naltrexone, buprenorphine or methadone can further complicate matters. This presentation will discuss therapeutic approaches, with an emphasis on opioid therapy, to pain management in patients with opioid dependence.
Aleksandra Zgierska, MD, PhD

6:00 pm - 8:00 pm
Special Dinner Presentation 
Optimizing Treatment for Opioid-addicted Adolescents and Young Adults:
The State of the Evidence
This presentation will characterize treatment-seeking youth addicted to prescription (and other) opioids, introduce participants to two model treatment programs, and review the state of the scientific literature on the treatment of prescription (and other) opioid dependence
among adolescents and young adults.
Sarah K. Moore, PhD, Senior Researcher, Capital Health Medical Center
Karen Carlini, CASAC, Associate Director, Dynamic Youth Community, Inc.
Sharon Levy, MD, Director, Adolescent Substance Abuse Pgm, Children’s Hospital 
Lisa A. Marsch, PhD, Director, Center for Tech & Behavioral Health, Dartmouth College
(Additional Fee to Participate, Click here for Invitation)
Presented in association with IAPCD.

Tuesday, June 9, 2015
Conference Hours 8:00 am - 1:15 pm, Registration open 7:00 am - 12:00 pm
8:00 am - 8:45 am
Sigma-1 Receptors: Important Modulators Of Opioid Responses
and the Development of Sigma-1 Receptor Antagonists as Co-analgesics.
Sigma-1 receptors are endoplasmic reticulum mobile receptors which are tonically active anti-opioid modulators.  SIRA, A Sigma-1-receptor blocker with development. These unique receptors were initially thought to be opioid receptors because they were bound by dextrorotatory benzomorphan derivatives [ (+) pentazocine]. They are now known to be important modulators of opioid responses.
Mellar Davis, MD
Gavril Pasternak, MD
8:45 am - 9:30 am 
Meeting Opioid Guideline Prescribing Requirements

This workshop will provide a hands on look at the tools, techniques and work flows for a physician practice to meet opioid prescribing guidelines.
William Brose, MD
9:30 am - 10:00 am
Improving Utilization and Outcomes of Urine Drug Testing
This session will provide an overview of appropriate use of urine drug testing (UDT) to identify and treatment substance use. Proper utilization can improve quality, reduce costs, and expand consumer access to treatment.
Michael Barnes, Esq.
Andrea Barthwell, MD, FASAM 
10:00 am - 10:45 am
 A primer and latest applications of urine drug testing
Gary M. Reisfield, MD
10:45 am - 11:00 am
Break with Exhibitors
11:00 am - 11:30 am
Selected Poster Presentations to audience

11:30 am - 1:00 pm
Opioid Analgesia and Marijuana - Questions of Balance
A balanced discussion of issues surrounding cannabis use by the chronic pain patient using opioid pharmacotherapy - including considerations of medical-scientific facts and fiction about cannabis; legal-regulatory  issues relevant to cannabis and its various use scenarios; ethical questions confronting clinicians caring for cannabis users; research on cannabis including its possible use to potentiate opioid analgesia.
Larry Driver, MD
Michael Schatman PhD

1:00 pm - 1:15 pm
Conference Closing Remarks 
Paul A. Sloan, MD & Mellar Davis, MD

 *Conference schedule and topics subject to change without notice

- - - - - - - -

 ICOO 2015 Conference Times
Saturday June 6, 2015
 Exhibitor Setup 2:30 pm to 5:00 pm
Attendee Registration 2:30 pm to 5:00 pm
Sunday June 7, 2015
Attendee and Exhibitor Registration 7:00 am to 5:00 pm
Conference day begins at 8:30 am -  day ends at 5:30 pm
Monday, June 8, 2015
Attendee and Exhibitor Registration 7:00 am to 5:00 pm
Conference day begins at 8:00 am - day ends at 5:15 pm
Tuesday, June 9, 2015
 Attendee and Exhibitor Registration 7:00am to 1:30pm
 Conference day begins at 8:00 am - 
Conference closes at 1:15 pm
 Exhibit Breakdown 1:30pm to 4:00pm

Please bookmark this page and check back periodically.
Schedule Subject to change without notice